Lord, Abbett & Co
PTGX icon

Lord, Abbett & Co’s Protagonist Therapeutics PTGX Stock Holding History

Lord, Abbett & Co’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.9M Buy
398,994
+235,535
+144% +$24.6M 0.14% 185
2026
Q1 		$17.2M Buy
+163,459
New +$14.5M 0.06% 296
2022
Q2 		– Sell
-275,787
Closed -$6.53M – 613
2022
Q1 		$6.53M Buy
275,787
+112,123
+69% +$3.16M 0.02% 527
2021
Q4 		$5.6M Buy
+163,664
New +$5.17M 0.01% 542
2021
Q3 		– Sell
-138,608
Closed -$6.22M – 680
2021
Q2 		$6.22M Buy
+138,608
New +$4.58M 0.02% 597

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Lord, Abbett & Co's PTGX Position: Q2 2026 in Review

Lord, Abbett & Co increased its Protagonist Therapeutics (PTGX) stake by 144% in Q2 2026, buying an estimated $24.6M and bringing the position to 398,994 shares worth $48.9M. The position accounts for 0.14% of the portfolio, ranked #185.

Lord, Abbett & Co first reported a position in PTGX in Q2 2021 and has held it in 5 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Lord, Abbett & Co held 398,994 shares of Protagonist Therapeutics worth $48.9M as of Q2 2026.
  • Lord, Abbett & Co bought 235,535 Protagonist Therapeutics shares in Q2 2026, an estimated $24.6M.
  • Protagonist Therapeutics made up 0.14% of Lord, Abbett & Co's portfolio in Q2 2026, its #185 holding.
  • Lord, Abbett & Co first reported a position in Protagonist Therapeutics in Q2 2021 and has held it in 5 quarters since.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.